January 7-10, 2018, San Francisco (USA)
Diadem will attend the conference to establish business partnerships with multinational Pharma and diagnostics companies.
Milan, Italy, December 21, 2018
Diadem, an academic spin-off active in early Alzheimer diagnostic, raises €1,5 million in its A Round led by Panakes Partners
Panakès Partners has led an investment round of ca. €1,5 million in Diadem an innovative startup based in Milan and London operating in the In Vitro Diagnostic sector for early diagnostic of Alzheimer.
Alzheimer’s affects more people today than cancer and heart disease combined and there are currently no disease modifying drugs approved on the market. Therapeutics in trials are expected to work better in people with limited brain damage, when patients show no or limited symptoms. With current diagnostic tools however, it is very difficult to identify patients at these early stages. Diadem’s potentially revolutionary new test is blood-based and according to strong preliminary data, should be more accurate, inexpensive and certainly non-invasive and should then solve one of the biggest bottlenecks in the race for a cure.
Diadem’s scientistific co-founder Prof Daniela Uberti, University of Brescia, says: “This financing round is instrumental to allow the company to validate and launch our diagnostic kit on the market. Prof. Maurizio Memo, the scientific co-founder of the company continued: “The momentum is ideal. There is finally scientific consensus in the community that brain damage from Alzheimer’s starts decades before symptoms appear and that therapies should be most effective when symptoms are not present.“
“We are excited of our investment in Diadem since we recognise the value of 15 years of R&D work, with progress potentially affecting one of the main unmet clinical needs of medicine today, the tratment of Alzhemer patients. We strongly believed in the scientific background of the founding team, the robustness of its initial clinical data and are confident that its management team, will lead the company to success!” said Diana Saraceni, Panakes General Partner.
“We are excited to work alongside Panakes, a fund focused on the sector, providing the right expertise and international network to the project. Our aim is not only to create value for the company but also for the entire Alzheimers’ patients community” commented Andreas Ballis Managing Director of the UK entity. “ We see a bright future for the company, as we are every day more excited about confirmatory data on our predictive accuracy; final validation for regulatory approval will shortly be completed in the coming months and this financing was key to secure our activities“ enthusiastically continued Simona Piccirella, Managing Director of the Italian entity.
Panakès investment also allowed the company to attract a significant number of talents in the company including advisors and company’s board members. Among them Francesco Granata, an industry veteran, former part of the Executive Committee at Biogen Idec (NASDAQ: BIIB) and Group Vice President for Schering-Plough Europe and Canada, Antonio Boniolo co-founder of DiaSorin one of the leading multinationals in the IVD space, Antonella Fassio a regulatory expert with 25 years’ experience in diagnostic product approvals and on the medical side Prof. Jeff Cummings, a leading key opinion leader in Alzheimer’s and Director Emeritus of Cleveland Clinic Center for Brain Health and Robert Dean, ex. Director Diagnostics & Experimental Medicine at Eli Lilly.
The company will progress the test through clinical trials and regulatory approval in the EU and US. The test is expected to have CE marking in Europe by the end of 2019.
July 22-26, 2018, Chicago (USA)
Diadem attended the 2018 AAIC, where last outcomes based on large longitudinal, multi-year studies of our diagnostic test were presented.
January 8-11, 2018, San Francisco (USA)
Diadem attended the conference and presented to multinational Pharma and diagnostics players to establish partnerships.
July 16-20, 2017, London (UK)
Diadem attended the AAIC conference in London in July 2017.
Prof. Daniela Uberti presented two posters on blood based biomarker and the redox profile in Alzheimer's and the significance in timely diagnosis.